Recombinant PBP2a/autolysin Conjugate As PLGA-based Nanovaccine Induced Humoral Responses with Opsonophagocytosis Activity, and Protection Versus Methicillin-resistant Infection

Overview

Journal Iran J Basic Med Sci

Publisher Mashhad University of Medical Sciences

Specialty General Medicine

Date 2022 Jun 3

PMID 35656080

Authors

Setareh Haghighat

Seyed Davar Siadat

Abbas Akhavan Sepahi

Mehdi Mahdavi

Affiliations

Soon will be listed here.

Abstract

Objectives: Methicillin-resistant (MRSA) reasons extreme infections, can resist various conventional antimicrobial agents, and cause morbidity and mortality worldwide. Vaccination seems to help modulate MRSA infections. Nanovaccine is considered a novel strategy in vaccine technology. The primary purpose of the present study was to develop a conjugate vaccine based on recombinant PBP2a and MRSA autolysin formulated in PLGA as a nanoparticle capable of enhancing protective responses against MRSA in the murine model.

Materials And Methods: Recombinant PBP2a and autolysin have been expressed and purified by nickel-nitrilotriacetic acid (Ni-NTA) affinity column and characterized by SDS-PAGE and western blot. PLGA was bound to recombinant proteins by using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDAC) and adipic acid dihydrazide (ADH) as a linker and spacer, respectively. Conjugation of recombinant proteins to PLGA was confirmed by the AFM assay, zeta potential, and size distribution, and its efficacy was evaluated in mice. Total IgG, IgG1, IgG2a, IgG2b, and IgM titers were analyzed to assess immune responses. Lastly, the bioactivity of antibodies was tested by using the opsonophagocytosis assay.

Results: Mice immunized with the r-PBP2a-r-autolysin-PLGA nanovaccine led to increased levels of opsonic antibodies and IgG1, IgG2a, IgG2b, and IgM when compared with other experimental groups. Our results confirmed that vaccination with nanovaccine could reduce the mortality rate against the sub-lethal dose of MRSA challenge. Furthermore, the nanovaccine could eliminate MRSA from the kidney of infected mice.

Conclusion: This study may provide valuable insights into the protective power of the r-PBP2a-r-autolysin-PLGA conjugate vaccine against MRSA infection.

Citing Articles

Immune Responses to Methicillin-Resistant Infections and Advances in the Development of Vaccines and Immunotherapies.

Scully J, Mustafa A, Hanif A, Tunio J, Tunio S Vaccines (Basel). 2024; 12(10).

PMID: 39460273 PMC: 11511289. DOI: 10.3390/vaccines12101106.

Newly designed nanoparticle-drug delivery systems against infection: a systematic review.

Kamarehei F, Saleh G, Hemmati J, Gohari S Int J Clin Exp Pathol. 2024; 17(4):96-107.

PMID: 38716352 PMC: 11070434. DOI: 10.62347/BVWH1940.

Monophosphoryl lipid A as a co-adjuvant in methicillin-resistant Staphylococcus aureus vaccine development: improvement of immune responses in a mouse model of infection.

Mirshekar M, Haghighat S, Mousavi Z, Abdolghaffari A, Yazdi M Immunol Res. 2024; 72(3):490-502.

PMID: 38383811 DOI: 10.1007/s12026-024-09456-x.

References

Miller L, Fowler V, Shukla S, Rose W, Proctor R . Development of a vaccine against Staphylococcus aureus invasive infections: Evidence based on human immunity, genetics and bacterial evasion mechanisms. FEMS Microbiol Rev. 2019; 44(1):123-153. PMC: 7053580. DOI: 10.1093/femsre/fuz030. View

Zhao L, Seth A, Wibowo N, Zhao C, Mitter N, Yu C . Nanoparticle vaccines. Vaccine. 2013; 32(3):327-37. DOI: 10.1016/j.vaccine.2013.11.069. View

Makadia H, Siegel S . Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier. Polymers (Basel). 2012; 3(3):1377-1397. PMC: 3347861. DOI: 10.3390/polym3031377. View

Haghighat S, Siadat S, Sorkhabadi S, Sepahi A, Mahdavi M . Cloning, expression and purification of autolysin from methicillin-resistant Staphylococcus aureus: potency and challenge study in Balb/c mice. Mol Immunol. 2016; 82:10-18. DOI: 10.1016/j.molimm.2016.12.013. View

Demento S, Cui W, Criscione J, Stern E, Tulipan J, Kaech S . Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype. Biomaterials. 2012; 33(19):4957-64. PMC: 5724530. DOI: 10.1016/j.biomaterials.2012.03.041. View

Marrack P, McKee A, Munks M . Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol. 2009; 9(4):287-93. PMC: 3147301. DOI: 10.1038/nri2510. View

Haghighat S, Siadat S, Sorkhabadi S, Sepahi A, Mahdavi M . A novel recombinant vaccine candidate comprising PBP2a and autolysin against Methicillin Resistant Staphylococcus aureus confers protection in the experimental mice. Mol Immunol. 2017; 91:1-7. DOI: 10.1016/j.molimm.2017.08.013. View

Oyewumi M, Kumar A, Cui Z . Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev Vaccines. 2010; 9(9):1095-107. PMC: 2963573. DOI: 10.1586/erv.10.89. View

Ali A, Shah T, Ullah R, Zhou P, Guo M, Ovais M . Review on Recent Progress in Magnetic Nanoparticles: Synthesis, Characterization, and Diverse Applications. Front Chem. 2021; 9:629054. PMC: 8314212. DOI: 10.3389/fchem.2021.629054. View

10.

Saini V, Jain V, Sudheesh M, Jaganathan K, Murthy P, Kohli D . Comparison of humoral and cell-mediated immune responses to cationic PLGA microspheres containing recombinant hepatitis B antigen. Int J Pharm. 2011; 408(1-2):50-7. DOI: 10.1016/j.ijpharm.2011.01.045. View

11.

Silva A, Soema P, Slutter B, Ossendorp F, Jiskoot W . PLGA particulate delivery systems for subunit vaccines: Linking particle properties to immunogenicity. Hum Vaccin Immunother. 2016; 12(4):1056-69. PMC: 4962933. DOI: 10.1080/21645515.2015.1117714. View

12.

Roth D, Senna J, Machado D . Evaluation of the humoral immune response in BALB/c mice immunized with a naked DNA vaccine anti-methicillin-resistant Staphylococcus aureus. Genet Mol Res. 2006; 5(3):503-12. View

13.

Ames P, Desjardins D, Pier G . Opsonophagocytic killing activity of rabbit antibody to Pseudomonas aeruginosa mucoid exopolysaccharide. Infect Immun. 1985; 49(2):281-5. PMC: 262011. DOI: 10.1128/iai.49.2.281-285.1985. View

14.

Scully I, Liberator P, Jansen K, Anderson A . Covering all the Bases: Preclinical Development of an Effective Staphylococcus aureus Vaccine. Front Immunol. 2014; 5:109. PMC: 3970019. DOI: 10.3389/fimmu.2014.00109. View

15.

Thomas C, Gupta V, Ahsan F . Influence of surface charge of PLGA particles of recombinant hepatitis B surface antigen in enhancing systemic and mucosal immune responses. Int J Pharm. 2009; 379(1):41-50. DOI: 10.1016/j.ijpharm.2009.06.006. View

16.

Genta I, Colonna C, Conti B, Caliceti P, Salmaso S, Speziale P . CNA-loaded PLGA nanoparticles improve humoral response againstS. aureus-mediated infections in a mouse model: subcutaneous vs. nasal administration strategy. J Microencapsul. 2016; 33(8):750-762. DOI: 10.1080/02652048.2016.1260661. View

17.

Bharali D, Sudha T, Cui H, Mian B, Mousa S . Anti-CD24 nano-targeted delivery of docetaxel for the treatment of prostate cancer. Nanomedicine. 2016; 13(1):263-273. DOI: 10.1016/j.nano.2016.08.017. View

18.

Danhier F, Ansorena E, Silva J, Coco R, Le Breton A, Preat V . PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012; 161(2):505-22. DOI: 10.1016/j.jconrel.2012.01.043. View

19.

Salatin S, Dizaj S, Khosroushahi A . Effect of the surface modification, size, and shape on cellular uptake of nanoparticles. Cell Biol Int. 2015; 39(8):881-90. DOI: 10.1002/cbin.10459. View

20.

Chen L, Li S, Wang Z, Chang R, Su J, Han B . Protective effect of recombinant staphylococcal enterotoxin A entrapped in polylactic-co-glycolic acid microspheres against Staphylococcus aureus infection. Vet Res. 2012; 43:20. PMC: 3353243. DOI: 10.1186/1297-9716-43-20. View